The Brk protein tyrosine kinase as a therapeutic target in cancer: Opportunities and challenges

Anti-Cancer Drugs

Volumn 15, Issue 2, 2004, Pages 107-111

  Harvey, Amanda J ^a   Crompton, Mark R ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast tumor; Brk; Proliferation; Protein tyrosine kinase; PTK6; Sik; Therapy

Indexed keywords

IMATINIB; PROTEIN BRK; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

BREAST TUMOR; CARCINOMA CELL; CELL FUNCTION; CELL PROLIFERATION; HUMAN; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

EID: 1542358939     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200402000-00002     Document Type: Review

References (29)

1. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, et al. Cloning and characterization of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumors. Oncogene 1994; 9:2383-2390.
2. Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res 2003; 13:409-419.
3. Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 1999; 5:1767-1777.
4. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003; 22:4212-4220.
5. Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B, et al. A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene 1995; 10:349-357.
6. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997; 15:799-805.
7. Easty DJ, Mitchell PJ, Patel K, Florenes VA, Spritz RA, Bennett DC. Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer 1997; 71:1061-1065.
8. Stamps AC, Davies SC, Burman J, O'Hare MJ. Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 1994; 57:865-874.
9. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ, et al. Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271:30956-30963.
10. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999; 253:78-87.
11. Shi Y. Mammalian RNAi for the masses. Trends Genet 2003; 19:9-12.
12. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003; 22:5006-5010.
13. Vasioukhin V, Tyner AL. A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci USA 1997; 94:14477-14482.
14. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002; 4:70-76.
15. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29:231-245.
16. Kamalati T, Jolin HE, Fry MJ, Crompton MR. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signaling to Pl 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000; 19:5471-5476.
17. O-Charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 2000; 60:1121-1128.
18. O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000; 18:155-161.
19. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98:10983-10985.
20. Mitchell PJ, Barker KT, Shipley J, Crompton MR. Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene 1997; 15:1497-1502.
21. Lee H, Kim M, Lee KH, Kang KN, Lee ST. Exon-intron structure of the human PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine kinase. Mol Cells 1998; 8:401-407.
22. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8:S14-S18.
23. Mitchell PJ, Sara EA, Crompton MR. A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 2000; 19:4273-4282.
24. Derry JJ, Richard S, Valderrama Carvajal H, Ye X, Vasioukhin V, Cochrane AW, et al. Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol 2000; 20:6114-6126.
25. Coyle JH, Guzik BW, Bor YC, Jin L, Eisner-Smerage L, Taylor SJ, et al. Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK. Mol Cell Biol 2003; 23:92-103.
26. Vidal M, Gigoux V, Garbay C. SH2 and SH3 domains as targets for anti-proliferative agents. Crit Rev Oncol Hematol 2001; 40:175-186.
27. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 2002; 277:34634-34641.
28. 15N resonance assignments of the human PTK6 SH2 domain. J Biomol NMR 2001; 19:291-292.
29. Koo BK, Kim MH, Lee ST, Lee W. Purification and spectroscopic characterization of the human protein tyrosine kinase-6 SH3 domain. J Biochem Mol Biol 2002; 35:343-347.